RE:Are Boston Scientific's Lotus Valve Woes Neovasc's Gain?All I can say is Neovasc is being headed up by a more trusted experienced management and has regulatory approval both in the U.S. and Europe. At year end it has 17.5 Mil in the bank; 48 patients with Tiera implants; and the experts assigned this stock to gain by 2975% over this year with a price tag high of $5.00. I do believe we are seeing our bottom right now and is poised to rebound.